These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 7510073

  • 1. [Clinical significance of prostate-specific antigen].
    Tveter KJ, Otnes B.
    Tidsskr Nor Laegeforen; 1994 Jan 20; 114(2):160-2. PubMed ID: 7510073
    [Abstract] [Full Text] [Related]

  • 2. [Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer].
    Hübler J, Jávor A.
    Orv Hetil; 1993 Jul 11; 134(28):1529-32. PubMed ID: 7688112
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF, Mensink HJ.
    Ned Tijdschr Geneeskd; 1999 Aug 21; 143(34):1733-8. PubMed ID: 10494319
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
    Goel T, Garg S.
    Urol Int; 2009 Aug 21; 82(3):286-90. PubMed ID: 19440015
    [Abstract] [Full Text] [Related]

  • 7. [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)].
    de la Taille A, Houlgatte A, Houdelette P, Berlizot P, Ramirez J, Ricordel I.
    Prog Urol; 1997 Apr 21; 7(2):240-5. PubMed ID: 9264766
    [Abstract] [Full Text] [Related]

  • 8. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
    Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM.
    Cancer; 2006 Apr 01; 106(7):1507-13. PubMed ID: 16518812
    [Abstract] [Full Text] [Related]

  • 9. [Prostate specific antigen and diagnosis of prostate cancer].
    Rigaud J, Bouchot O.
    Rev Prat; 2003 Dec 31; 53(20):2229-36. PubMed ID: 15018076
    [Abstract] [Full Text] [Related]

  • 10. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J, Högstedt B.
    Scand J Urol Nephrol; 2002 Dec 31; 36(5):330-8. PubMed ID: 12487736
    [Abstract] [Full Text] [Related]

  • 11. The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
    Tchetgen MB, Oesterling JE.
    Urol Clin North Am; 1995 May 31; 22(2):333-44. PubMed ID: 7539179
    [Abstract] [Full Text] [Related]

  • 12. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M, Bastian M, Steiner M, Zingler C, Müller M, Wolff JM, Seiter H, Schuff-Werner P.
    Anticancer Res; 2000 May 31; 20(6D):4995-6. PubMed ID: 11326656
    [Abstract] [Full Text] [Related]

  • 13. Elevated prostate-specific antigen: a case report and analysis.
    Hicks RJ.
    J Fam Pract; 1993 Sep 31; 37(3):284-8. PubMed ID: 7691981
    [Abstract] [Full Text] [Related]

  • 14. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    J Urol; 2001 Oct 31; 166(4):1339-42. PubMed ID: 11547069
    [Abstract] [Full Text] [Related]

  • 15. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J, Raventós CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I, Andreu J.
    J Urol; 1997 Aug 31; 158(2):502-4. PubMed ID: 9224333
    [Abstract] [Full Text] [Related]

  • 16. [Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases].
    Kato M, Okada K.
    Hinyokika Kiyo; 1993 Mar 31; 39(3):221-3. PubMed ID: 7685140
    [Abstract] [Full Text] [Related]

  • 17. [Pathological basis for elevation of serum prostate specific antigen].
    Xia TL, Deng FM, Feng T.
    Zhonghua Yi Xue Za Zhi; 1994 May 31; 74(5):306-8, 327. PubMed ID: 7525028
    [Abstract] [Full Text] [Related]

  • 18. [Usefulness of free prostate specific antigen in the detection of prostate cancer].
    Azócar G, Castillo O, Van Cauwelaert R, Cumsille MA, Campero JM, Aguirre C, Wöhler C.
    Rev Med Chil; 1999 Feb 31; 127(2):151-7. PubMed ID: 10436694
    [Abstract] [Full Text] [Related]

  • 19. Role of transurethral biopsy sampling of the prostate to diagnose prostate cancer in men undergoing surgical intervention for benign prostatic hyperplasia.
    Bales GT, Flynn TJ, Kynaston HG, Golash A, Hart A, Kim HL, Gerber GS.
    Tech Urol; 2000 Sep 31; 6(3):201-4. PubMed ID: 10963487
    [Abstract] [Full Text] [Related]

  • 20. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME.
    Clin Lab Sci; 2001 Sep 31; 14(2):102-7. PubMed ID: 15625982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.